Paul A. Bunn, Jr, MD

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors (TKIs)

Many patients have comorbid diseases and are very sick when they are diagnosed with lung cancer

TKIs are oral, do not require an IV and they do not have grade 3 and 4 life-threatening toxicities

Sick patients who have lung cancer should have molecular testing to see if they are eligible to use TKIs

Videos

Paul A. Bunn, Jr, MD,  explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors (TKIs)

Paul A. Bunn, Jr, MD | Authors

Articles

Treating Advanced-Stage Lung Cancer with TKIs